Literature DB >> 21321117

Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells.

Soyoung Cheon1, Ji Hyung Lee, Sunyoung Park, Sa Ik Bang, Wang Jae Lee, Do-Young Yoon, Sung-Soo Yoon, Taesung Kim, Hyeyoung Min, Byung Joo Cho, Hyong Joo Lee, Ki Woong Lee, Seung Hwan Jeong, Hyunjeong Park, Daeho Cho.   

Abstract

IL-32 was recently identified as a proinflammatory cytokine that is induced by IL-18 in natural killer (NK) cells and is highly correlated with inflammatory disorders. However, the relationship between IL-32 and tumor progression is still unknown. In this study, we investigated whether overexpression of IL-32 affects susceptibility of chronic myeloid leukemia (CML) cells to NK cells. Interestingly, IL-32α-overexpressing CML cell lines, K562, Kcl22, and BV173, showed higher NK cell-mediated killing. Flow cytometry analysis revealed that overexpression of IL-32α induced increased expression of Fas and UL16-binding protein 2 (ULBP2) in CML cells. The direct relationship between overexpression of surface molecules by IL-32α and increased NK cell-mediated killing was confirmed by Fas or ULBP2 siRNA transfection. IL-32α-induced Fas and ULBP2 expression are regulated p38 MAPK. In addition, the transcription factor Ets1 plays a key role in ULBP2 specific expression by IL-32α overexpression in ULBP family members. Taken together, these data show that IL-32α stimulates Fas and ULBP2 expression via activation of p38 MAPK, which increases NK susceptibility of CML cells. Enhanced NK cell susceptibility of CML cells by IL-32α overexpression may improve the efficiency of NK cell-based immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321117      PMCID: PMC3069408          DOI: 10.1074/jbc.M110.159756

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.

Authors:  J M Kyriakis; J Avruch
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

Review 2.  Roles of the NKG2D immunoreceptor and its ligands.

Authors:  David H Raulet
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

3.  The choices of a natural killer.

Authors:  Giorgio Trinchieri
Journal:  Nat Immunol       Date:  2003-06       Impact factor: 25.606

4.  The role of the NKG2D immunoreceptor in immune cell activation and natural killing.

Authors:  Amanda M Jamieson; Andreas Diefenbach; Christopher W McMahon; Na Xiong; James R Carlyle; David H Raulet
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

5.  Differential roles of constitutively activated ERK1/2 and NF-kappa B in cytotoxicity and proliferation by human NK cell lines.

Authors:  Shujuan Liang; Jian Zhang; Haiming Wei; Rui Sun; Zhigang Tian
Journal:  Int Immunopharmacol       Date:  2005-01-25       Impact factor: 4.932

6.  Interleukin-32: a cytokine and inducer of TNFalpha.

Authors:  Soo-Hyun Kim; Sun-Young Han; Tania Azam; Do-Young Yoon; Charles A Dinarello
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

7.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Authors:  S Bauer; V Groh; J Wu; A Steinle; J H Phillips; L L Lanier; T Spies
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

8.  Transcription factor Ets-1 mediates ischemia- and vascular endothelial growth factor-dependent retinal neovascularization.

Authors:  Daisuke Watanabe; Hitoshi Takagi; Kiyoshi Suzuma; Izumi Suzuma; Hideyasu Oh; Hirokazu Ohashi; Seiji Kemmochi; Akiyoshi Uemura; Tomonari Ojima; Eri Suganami; Noriko Miyamoto; Yasufumi Sato; Yoshihito Honda
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  A second lineage of mammalian major histocompatibility complex class I genes.

Authors:  S Bahram; M Bresnahan; D E Geraghty; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

10.  Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors.

Authors:  S K Logan; M J Garabedian; C E Campbell; Z Werb
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

View more
  17 in total

Review 1.  Aptamers Against Pro- and Anti-Inflammatory Cytokines: A Review.

Authors:  Maryam Boshtam; Seddigheh Asgary; Shirin Kouhpayeh; Laleh Shariati; Hossein Khanahmad
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

2.  Interleukin-32 promotes lipid accumulation through inhibition of cholesterol efflux.

Authors:  Zonglei Xu; Aizhi Dong; Zerui Feng; Jing Li
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

Review 3.  Role of interleukin-32 in chronic rhinosinusitis.

Authors:  Anjeni Keswani; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-02

4.  Intracellular interaction of interleukin (IL)-32α with protein kinase Cε (PKCε ) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells.

Authors:  Jeong-Woo Kang; Yun Sun Park; Dong Hun Lee; Jung-Hee Kim; Man Sub Kim; Yesol Bak; Jintae Hong; Do-Young Yoon
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

Review 5.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

Review 6.  Role of interleukin-32 in cancer biology.

Authors:  Haimeng Yan; Donghua He; Xi Huang; Enfan Zhang; Qingxiao Chen; Ruyi Xu; Xinling Liu; Fuming Zi; Zhen Cai
Journal:  Oncol Lett       Date:  2018-05-07       Impact factor: 2.967

7.  The role of IL-32 in cutaneous T-cell lymphoma.

Authors:  Hiraku Suga; Makoto Sugaya; Tomomitsu Miyagaki; Makiko Kawaguchi; Hideki Fujita; Yoshihide Asano; Yayoi Tada; Takafumi Kadono; Shinichi Sato
Journal:  J Invest Dermatol       Date:  2013-11-13       Impact factor: 8.551

Review 8.  The use of microRNA by human viruses: lessons from NK cells and HCMV infection.

Authors:  Tal Goldberger; Ofer Mandelboim
Journal:  Semin Immunopathol       Date:  2014-09-19       Impact factor: 11.759

9.  IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling.

Authors:  Hyung-Mun Yun; Kyung-Ran Park; Eun-Cheol Kim; Sang Bae Han; Do Young Yoon; Jin Tae Hong
Journal:  Oncotarget       Date:  2015-04-20

10.  Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals.

Authors:  H-M Yun; J H Oh; J-H Shim; J O Ban; K-R Park; J-H Kim; D H Lee; J-W Kang; Y H Park; D Yu; Y Kim; S B Han; D-Y Yoon; J T Hong
Journal:  Cell Death Dis       Date:  2013-05-23       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.